Eli Lilly (LLY) Total Non-Current Liabilities (2016 - 2025)
Eli Lilly's Total Non-Current Liabilities history spans 17 years, with the latest figure at $50.7 billion for Q4 2025.
- For Q4 2025, Total Non-Current Liabilities rose 40.61% year-over-year to $50.7 billion; the TTM value through Dec 2025 reached $50.7 billion, up 40.61%, while the annual FY2025 figure was $50.7 billion, 40.61% up from the prior year.
- Total Non-Current Liabilities reached $50.7 billion in Q4 2025 per LLY's latest filing, roughly flat from $50.9 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $50.9 billion in Q3 2025 to a low of $21.6 billion in Q4 2022.
- Average Total Non-Current Liabilities over 5 years is $31.1 billion, with a median of $26.3 billion recorded in 2021.
- Peak YoY movement for Total Non-Current Liabilities: decreased 18.49% in 2022, then surged 48.77% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $24.6 billion in 2021, then decreased by 12.29% to $21.6 billion in 2022, then grew by 19.81% to $25.8 billion in 2023, then soared by 39.53% to $36.1 billion in 2024, then surged by 40.61% to $50.7 billion in 2025.
- Per Business Quant, the three most recent readings for LLY's Total Non-Current Liabilities are $50.7 billion (Q4 2025), $50.9 billion (Q3 2025), and $43.6 billion (Q2 2025).